Quanticate Launches Monitoring Services Following the ICH GCP E6(R2) Addendum
Quanticate has launched its statistical monitoring service as an extension of its consultancy offering in response to recent amendments to the ICH GCP E6(R2) guidelines which focus on incorporating RBM into trial design. Quanticate will use the RBM approach a long with the evaluation of these designs to conduct tests in order to guide decisions surrounding investigations into data discrepancies and identifying where site directed monitoring visits may be necessary.
Read the full release here.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
